Trypanosomes are protozoan parasites of medical and veterinary importance. 
Nagana in cattle. Man is protected from this subspecies of trypanosomes by a toxic subtype of high density lipoproteins (HDLs) called the trypanosome lytic factor (TLF). The toxic molecule in TLF is believed to be the haptoglobin-related protein that when bound to hemoglobin kills the trypanosome via oxidative damage initiated by its peroxidase activity. The amount of lytic activity in serum varies widely between different individuals with up to a 60-fold difference in activity.
In addition, an increase in the total amount of lytic activity occurs during the purification of TLF, suggesting that an inhibitor of TLF (ITLF) exists in human serum. We now show that the individual variation in trypanosome lytic activity in serum correlates to variations in the amount of IT.n. Immunoblots of ITLF probed with antiserum against haptoglobin recognize a 120-kDa protein, indicating that haptoglobin is present in partially purified ITLF. Haptoglobin involvement is further shown in that it inhibits TLF in a manner similar to ITLF. Using an anti-haptoglobin column to remove haptoglobin from ITLF, we show that the loss of haptoglobin coincides with the loss of inhibitor activity. Addition of purified haptoglobin restores inhibitor activity. This indicates that haptoglobin is the molecule responsible for inhibition and therefore causing the individual variation in serum lytic activity.
Trypanosomes are flagellated protozoan parasites that cause disease in man and domestic livestock (1) . In man, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense cause African sleeping sickness. In animals, the disease Nagana is caused by the parasite Trypanosoma brucei brucei. These three subspecies of trypanosomes are morphologically, biochemically, and antigenically indistinguishable and differ only in their host range and pathologic presentation (2) . The difference in host specificity is caused by a nonimmune killing factor in human serum to which the African sleeping sickness trypanosomes are resistant (3) .
The trypanocidal activity of normal human serum has been localized to a minor subset of high density lipoproteins (HDLs) called trypanosome lytic factor (TLF), with the majority of serum HDL being nontoxic to trypanosomes (4) . Other studies indicate that a number of HDL subclasses might be cytotoxic to T. b. brucei, though the very high density (1.21-1.24 g/ml) TLF-containing subclass appears to be more potent (5) . Interestingly, Tomlinson and co-workers (6) have shown that in Tangier patients deficient in HDLs, the lytic activity is associated with nonlipoprotein complexes of 150-600 kDa and of >1000 kDa. The relationship of this lytic activity to HDLmediated lysis is unknown.
The cellular pathway for TLF-mediated lysis of T. b. brucei has been established (7) . TLF is taken into T. b. brucei by receptor-mediated endocytosis and targeted to the lysosome. Here it causes disruption of the organelle and eventual autodigestion of the parasite. TLF differs from nonlytic HDL in having a higher density (1.21-1.24 g/ml) and in containing two characteristic apolipoproteins (4), paraoxonase/arylesterase (8) and the haptoglobin-related protein (9, 10). Reconstitution studies showed that these two proteins, combined in micellar form, are sufficient to cause lysis (11) . The haptoglobin-related protein has been shown to be essential to the lytic process, which it initiates with its peroxidase activity (10) .
The amount of lytic activity in human serum varies between different individuals (5, (12) (13) (14) (15) . This variation has been attributed to differing amounts of the lytic molecule (5). However, it was noted that, despite starting with widely varying amounts of serum lytic activities, the total amount of TLF recovered was relatively constant among individuals (S.L.H., unpublished data). In addition, it was observed that during the purification of TLF, the total amount of lytic activity increased (4). These observations lead to speculation that a natural inhibitor existed in human serum and that variation in its level accounted for the differences in the amount of lytic activity in individual sera.
In this paper we show that there is an inhibitor of TLF (ITLF) present in normal human serum and that this inhibitor is haptoglobin. Haptoglobin is a serum protein that binds free hemoglobin and enters the liver by receptor-mediated endocytosis (16 (1995) 10263 Individual Variation. Human blood (10 ml) was collected from five normal healthy individuals. Serum was isolated, adjusted to a final density of 1.26 g/ml with NaBr and centrifuged for 25 hr at 15°C at 50,000 rpm in a microultracentrifuge (Beckman TL-100). Following centrifugation lipoprotein-containing fractions (<1.26 g/ml) and lipoproteindeficient fractions (>1.26 g/ml), which are equivalent to TLF and ITLF respectively, were collected. These were dialyzed overnight at 4°C against PBS/EDTA. The serum and the lipoprotein fractions were assayed for lytic activity, whereas the lipoprotein-deficient fraction was assayed for inhibitor activity.
Partial Purification of TLF and ITLF. TLF was purified by established procedures (4). The inhibitor was purified from 400 ml of normal human serum on a series of NaBr ultracentrifugations with the final density of 1.28 g/ml. Serum lipoproteins were removed leaving the bottom lipoprotein-deficient fraction. This lipoprotein-deficient serum was then washed with 100 ml of PBS/EDTA in a Centricone 30, Centriflo ultrafiltration membrane cones (Centricon, Danvers, MA) to remove the NaBr. The sample was further fractionated by CL6B size-exclusion, hydroxyapatite, and TSK G3000SW HPLC size-exclusion column chromatography. Fractions from each column with inhibitor activity were saved and run on the subsequent column. Partially purified TLF and ITLF were stored at -70°C for no more than 6 months.
Haptoglobin Affinity Column. The haptoglobin affinity resin was made by coupling 1 ml of Aminolink resin (Pierce) with 4 mg of rabbit anti-human haptoglobin antiserum (Sigma). Inhibitor (200 ,ug) was mixed with the anti-haptoglobin resin (0.5 ml) "in batch" at 26°C for 3 hr. The anti-haptoglobin resin was washed with 2.5 ml of PBS containing 0.5 mM EDTA, and the eluate was concentrated in a Centricone 30 (Centricon) ultrafiltration cone to 400 ,ul.
Quantification of Haptoglobin. The amount of human serum haptoglobin was quantified by the University of Alabama at Birmingham Hospital using a Kallestad QM300 antibody pack (Sanofi Diagnostics Pasteur, Chaska, MN). The assay is based on use of a nephelometer to monitor the formation of antigen-antibody complexes (17, 18) .
Hemolytic Anemia Patient. A serum sample from a patient with hemolytic anemia and iron-overload disease was also examined for lytic activity and haptoglobin concentration. The patient has an unstable hemoglobin leading to intravascular hemolysis. Because of the accompanying iron overload disorder, the patient undergoes biweekly phlebotomies. Serum was obtained from one of these phlebotomies with the patient's consent.
RESULTS
Role of Inhibitor in Individual Variation. The cause of individual variation in serum lytic activity has been a mystery for some time. We knew that an overall 30-fold increase in lytic activity occurred when HDLs were separated from the lipoprotein-deficient proteins (4), indicating the presence of an ITLF in the lipoprotein-deficient fraction. Therefore, we compared the variation of the lytic activities of TLF and the inhibitory activity of ITLF with the variation in serum lytic activity in five healthy individuals to see if any relationship existed. Serum levels of lytic activity were seen to vary from 0.015 to 0.94 units/gl (Fig. 1 Left) . After partial purification of TLF by ultracentrifugation, the variation in lytic activity between individuals was found to be minimal and had no significant correlation with the amount of serum lytic activity (Fig. 1 Center). However, ITLF activity varied significantly and in an inverse manner to the variation in serum lytic activity (Fig. 1 Right). On the basis of these observations, we propose that the serum levels of ITLF purified haptoglobin to the haptoglobin-deficient solution restored inhibitor activity to 100%, indicating that loss of lytic activity was due to the removal of haptoglobin and not the inadvertent removal of some other molecule.
Role of Haptoglobin in Individual Variation. Consistent with the idea that haptoglobin is the major inhibitor of lytic activity in human sera, the variation in the amount of haptoglobin in serum (Fig. 5 Upper) correlates with the variation in the level of inhibitor activity (Fig. 1 Right) . Plotting the amount of lytic activity in serum against the inverse of the concentration of haptoglobin in serum, there was a linear relationship between the two (r = 0.967; P = 0.007) (Fig. 5 Lower) . These results reconfirm that haptoglobin is the major inhibitor of TLF-mediated lysis present in human serum and indicate that it accounts for the individual variation in lytic activity seen in intact human serum.
Serum lytic activity and haptoglobin levels were then examined in a patient with hemolytic anemia to see if a pathophysiologic decrease in haptoglobin (21) would lead to an increase in lytic activity. As expected, the haptoglobin levels were very low (<0.05 mg/ml). When the serum lytic activity was examined, it was found to be at least 9-fold higher than that of any of the healthy patients (8.2 units/,ul). When this information was included as a data point (closed circle), the inverse linear relationship was even more significant (r = 0.999; P = 0.001) (Fig. 5 Lower Inset).
DISCUSSION
This research indicates that the level of human protection against T. b. brucei is not solely based on the presence of a cytotoxic molecule but also upon the amount of an inhibitor to the toxin present in blood. Furthermore, this inhibitory molecule, haptoglobin, is responsible for the variation of TLF activity seen in sera from different individuals. Thus, it seems that a balance exists in serum between haptoglobin and the haptoglobin-related protein, where the greater the ratio of haptoglobin-related protein to haptoglobin, the greater the defense against trypanosome infection.
Haptoglobin is an acute-phase response protein that increases during systemic tissue injury (22) . Since this is a protein Inverse relationship between haptoglobin concentrations and serum lytic activity. The serum lytic activity was plotted against the inverse of the serum haptoglobin concentration for the five healthy patients examined in Fig. 1 (a) . (Inset) Same data (0) but plotted with the results from one hemolytic anemia patient (0). whose concentration changes during times of illness, its effect on African trypanosomiasis may be dynamic. In mice it has been shown that 3 days after infection with T. brucei, serum levels of haptoglobin increase (23) . This is somewhat counterintuitive, since an increase in an inhibitor would mean a decrease in protection. However, in hemolytic anemia patients, there is a decrease of haptoglobin (21) because it binds to hemoglobin and is cleared into the liver cells. Since one of the symptoms of the first stage of African sleeping sickness is hemolytic anemia (ref. 24, p. 793), it is tempting to speculate that there is a decrease in haptoglobin, and therefore inhibitor, as the disease progresses, leading to an increase in TLFmediated lysis. In the one hemolytic anemia patient examined in our studies, the levels of lytic activity were at least 9-fold higher and the haptoglobin levels were at least 9-fold lower than any healthy patient examined, indicating that this enhancement can occur. If it turns out that haptoglobin is preferentially cleared during the initial stages of trypanosome infection, it may prove to be an important part of how this defense mechanism works.
Along with the pathophysiologic changes in haptoglobin concentration, the balance between haptoglobin and the haptoglobin-related protein can also be regulated on a genomic level. Hypohaptoglobinemia and ahaptoglobinemia are inheritable traits found in African Americans (25, 26) but are almost never found in Caucasians (27) . Because in Africa there is a high incidence of diseases that cause hemolytic anemia, and therefore a clinical decrease in haptoglobin, much of the research has been performed on African Americans. These studies found that 2.8-4.8% of African Americans are ahaptoglobinemic and 10.8-15.2% are hypohaptoglobinemic (25, 26) . It is interesting to note that the individual with the lowest level of haptoglobin and highest level of serum lytic activity from our healthy donors was an African American. Although there remains some question as to whether this decrease in haptoglobin is the result of an alteration in the haptoglobin gene or a gene regulating haptoglobin expression (26, 28) , the number of individuals with these traits is still very significant. To put this data in perspective, the heterozygote sickle cell trait, which is believed to have been selected for by malaria, is present in only 8% of African Americans (ref. 24, p. 1544) .
The other way that the haptoglobin-related/haptoglobin ratio could be increased at the genomic level is to have an increase in the number of haptoglobin-related genes. This has been found to be true (29) with as many as five additional copies of the haptoglobin-related gene being present in African Americans. Although our evidence showed little variation in the amount of TLF between different individuals, it may be that among those of African lineage, the amount of TLF is enhanced. The percentage of African Americans with this amplification is still uncertain though in their study Maeda et al. found multiple copies in 5 of the 15 unrelated individuals studied (29) .
The difference between T b. brucei and T b. rhodesiense has always been subtle. These subspecies are morphologically and biochemically indistinguishable and are separated solely upon their susceptibility to human serum. As shown previously and in our studies, the levels of lytic activity in serum vary between individuals (5, 12-15). The prevailing assumption has been that the trypanosomes could be neatly classified as either resistant or susceptible to human serum. However, there have been some studies that indicate that the T brucei exhibits a continuum of relative susceptibility to TLF with some organisms being lysed by one individual's serum but not another's (15, 30) . This would be consistent with a decrease in inhibitor and an increase in toxin, both having been selected for in those of African lineage. If trypanosomes were only resistant or sensitive, there would be no advantage to increased levels of TLF activity in serum and therefore no selective pressure. Although there is no proof that African trypanosomiasis was the selective pressure that promoted the decrease of haptoglobin and the increase of haptoglobin-related protein in African populations, it would explain the observed variations in haptoglobin and haptoglobin-related protein seen in African Americans. If proven to be true, this could be of great importance in combating African sleeping sickness.
